Pluristem To Terminate CLI Study Following DMC Recommendation - Quick Facts

Pluristem Therapeutics Inc. (PSTI) announced that the independent Data Monitoring Committee of its global pivotal Phase III study for the treatment of critical limb ischemia or CLI issued its recommendation letter that the study is unlikely to meet the primary endpoint by the time of final analysis.

Meanwhile, DMC noted that PLX-PAD was well tolerated and no significant safety concerns were raised during the study.

Following the DMC's recommendation, Pluristem said it has decided to terminate the CLI study.

Pluristem CEO and President, Yaky Yanay, stated "We are deeply disappointed by the outcome of the CLI interim analysis,"

The company said it plans to focus on different therapeutic areas in its pipeline and expects three clinical readouts within the coming calendar year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT